Figure 3. SGLT-2i Mechanisms of systematic and cardiorenal effects.
SGLT-2i=Sodium-Glucose Cotransporter-2 Inhibitors, NLPRP3=Nucleotide-binding Oligomerization Domain, Leucine-rich Repeat and Pyrin Domain-containing 3, EPO=Erythropoietin
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.